|
||||||||
Company Profile | ||||||||
Chairman | CEO | Spokesperson | Tel | Address | Date of Listing (Regular) | |||
---|---|---|---|---|---|---|---|---|
Christopher Tsai | Michael Kang | Michael Kang | (02)27951777 | 1F,No.28, Ln. 36 , Xinhu 1st Rd.Neihu Dist.,Taipei City 11497, , Taiwan | 2007/07/26 | |||
Industry | Main Business | |||||||
Biotechnology and Medical Care | BIONET is the first established and leading cord blood bank in Taiwan. The two major business are stem cell storage & therapy, and genetic testing. The services include: 1.Cord-Blood (CB) Storage: CB contains Hematopoietic Stem Cell (HSC), and it is the main source of human blood and immune system. It can cure the blood, immune system, and metabolism related diseases. 2.Mesenchymal Stem Cell (MSC) Storage: MSC can differentiate into tissues such as bones and nerves. It has many advantages such as the homing tendency and can adjust the immune reaction. 3.Stem Cell Revitalizer (SCR) Storage: From the mother’s placenta we have extracted the valuable SCR which contains ingredients of anti-aging effects. 4.Spinal Muscular Atrophy (SMA) Genetic Test: SMA is an autosomal recessive disorder with a carrier frequency of 1/25-1/30. If husband and wife are both carriers, 1/4 chance the baby is affected. Currently there is no cure, and can only prevent through pre-birth screening. |
Market Information ( 2024/04/25 ) | |||||||||||
Shr. Vol. | Highest | Lowest | Closed | Change | Transaction | TurnOver(%) | long margin balance (1,000shr.) |
Short margin balance (1,000shr.) |
|||
---|---|---|---|---|---|---|---|---|---|---|---|
1205.747 | 69.40 | 62.30 | 69.40 | 6.30 | 1026 | .00 | 3,625 | 17 | |||
Trading method | Fun purchase price or securities pneeded on T day |
Announcement of Irregularity (2024/04/25) |
TPEx measures adopted (2024/04/25) |
With warrants | Can be shorted or margined? | Detail | |||||
Normal | N | N | N | N | Y | Today | History |
Financial Reports | |||||
---|---|---|---|---|---|
Cash Flows | Items | ||||
Amount (NT$ thousand) |
|||||
Cash flows from operating activities | |||||
Cash flows from investing activities | |||||
Cash flows from financing activities | |||||
Balance Sheets |
Current assets | ||||
Non-current assets | |||||
Total assets | |||||
Current liabilities | |||||
Non-current liabilities | |||||
Total liabilities | |||||
Share capital | |||||
Capital surplus | |||||
Retained earnings | |||||
Other equity interest | |||||
Treasury shares | |||||
Total equity attributable to owners of parent | |||||
Non-controlling interests | |||||
Total equity | |||||
Book Value per share(NT$) | |||||
Comprehensive Income | Operating revenue | ||||
Operating costs | |||||
Gross profit from operations | |||||
Operating expenses | |||||
Net other income (expenses) | |||||
Net operating income | |||||
Non-operating income and expenses | |||||
Profit before tax | |||||
Tax expense | |||||
Profit from continuing operations | |||||
Profit from discontinued operations | |||||
Profit | |||||
Other comprehensive income | |||||
Comprehensive income | |||||
Basic earnings per share |
Auditor's report on latest financial statements: auditor's report: |
More detail:MOPS。 |
Foreign issuers’ information is disclosed in consolidated statements. |